Bellerophon Therapeutics (NASDAQ:BLPH) and Shiseido (OTCMKTS:SSDOY) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and valuation.
This is a breakdown of current recommendations and price targets for Bellerophon Therapeutics and Shiseido, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Institutional & Insider Ownership
22.0% of Bellerophon Therapeutics shares are owned by institutional investors. 21.4% of Bellerophon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Volatility and Risk
Bellerophon Therapeutics has a beta of -0.58, suggesting that its share price is 158% less volatile than the S&P 500. Comparatively, Shiseido has a beta of 0.33, suggesting that its share price is 67% less volatile than the S&P 500.
This table compares Bellerophon Therapeutics and Shiseido’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Bellerophon Therapeutics and Shiseido’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Bellerophon Therapeutics||N/A||N/A||-$24.73 million||($3.06)||-1.49|
|Shiseido||$8.63 billion||3.44||-$109.60 million||N/A||N/A|
Bellerophon Therapeutics has higher earnings, but lower revenue than Shiseido.
Bellerophon Therapeutics beats Shiseido on 8 of the 12 factors compared between the two stocks.
Bellerophon Therapeutics Company Profile
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 2 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; that has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that is in Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension, pulmonary hypertension associated with pulmonary edema from high altitude sickness, and COVID-19 patients. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
Shiseido Company Profile
Shiseido Company, Limited engages in the production and sale of cosmetics in Japan and internationally. The company offers fragrances; skincare products, shampoo, and other haircare products, as well as body care products; and hair care and styling products, as well as hair color and perm solutions for hair salons. It also conducts restaurant and food, and retail businesses; and operates beauty salons. In addition, the company operates and supports SABFA, a professional hair makeup training school. It sells its products through department stores, specialty stores, drug stores, and general merchandising stores. The company was founded in 1872 and is headquartered in Tokyo, Japan.
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.